Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Spago Nanomedical AB (publ)
AB
Active
Org 5565745048
Scheelevägen 22, 223 63
Lund
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 1999 · 26 years old
13 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Spago Nanomedical AB (publ)
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
5M
4M
2M
1M
0M
2020: 0M
0M
2020
2021: 1M
1M
2021
2022: 0M (-100% vs 2021)
0M
-100%
2022
2023: 3M
3M
2023
2024: 4M (+33% vs 2023)
4M
+33%
2024
EBITDA
SEK millions
0M
-12M
-24M
-36M
-49M
2020: -19M
-19M
2020
2021: -39M (-105% vs 2020)
-39M
-105%
2021
2022: 0M (+100% vs 2021)
0M
2022
2023: -37M
-37M
2023
2024: -26M (+30% vs 2023)
-26M
+30%
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
4 324
3 098
1
660
342
Staff expenses
—
—
—
—
—
EBITDA
−26 376
−37 497
−39
−38 816
−18 600
Depreciation & amort.
−293
−271
−0
−376
−362
EBIT
−26 669
−37 768
−39
−39 192
−18 962
Net financials
−12 832
−4 484
—
120
34
Profit before tax
−32 495
−42 252
−39
−39 071
−18 928
Tax
−0
−0
−0
−0
−0
Net profit
−32 495
−42 252
−39
−39 071
−18 928
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
38 308
49 312
206
191 624
162 820
Equity
33 235
41 317
197
184 812
159 675
Long-term debt
0
0
0
0
0
Short-term debt
4 588
7 804
9
6 812
3 146
Total debt
4 588
7 804
9
6 812
3 146
Financial ratios
5-year trend
EBITDA margin
−610,0 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
86,8 %
This company
38,2 %
Market median
This company
Market median
127% above market
2020
2024
Return on equity
−97,8 %
This company
18,4 %
Market median
This company
Market median
632% below market
2020
2024
Net profit margin
−751,5 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2020
2024
Asset turnover
0,11×
This company
1,12×
Market median
This company
Market median
90% below market
2020
2024
Debt / equity
0,15×
This company
0,62×
Market median
This company
Market median
76% below market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Spago Nanomedical AB (publ)
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
